Bringing Precision Medicine to Neuroscience Drug Development
A UK clinical-stage biotech company using digital biomarkers to develop targeted treatments for areas of high unmet need in psychiatry and neurology
Bringing Precision Medicine to Neuroscience Drug Development
A UK clinical-stage biotech company using digital biomarkers to develop targeted treatments for areas of high unmet need in psychiatry and neurology
Getting The Right Patient On The Right Drug
Biological differences between patients are a major reason neuroscience drugs often fail in clinical trials. Monument Tx are tackling this by using digital biomarkers to identify patients with similar brain biology, to increase their likelihood of responding to specific treatments.
Precision medicine, which has tripled drug approval rates in cancer by targeting the right patients, is being applied by Monument Tx to bring new hope for effective treatments in critical areas of psychiatry and neurology.
Clinical Stage Pipeline With Near Term Commercial Potential
Our pipeline includes two core treatments initially targeting cognitive impairment associated with schizophrenia and neuroinflammation. Leveraging proprietary digital biomarkers and novel formulations of well-characterized CNS-active small molecules, we are accelerating clinical development to achieve rapid progress in therapeutic innovation.
Getting The Right Patient On The Right Drug
Biological differences between patients are a major reason neuroscience drugs often fail in clinical trials. Monument Tx are tackling this by using digital biomarkers to identify patients with similar brain biology, to increase their likelihood of responding to specific treatments.
Precision medicine, which has tripled drug approval rates in cancer by targeting the right patients, is being applied by Monument Tx to bring new hope for effective treatments in critical areas of psychiatry and neurology.
Clinical Stage Pipeline With Near Term Commercial Potential
Our pipeline includes two core treatments initially targeting cognitive impairment associated with schizophrenia and neuroinflammation. Leveraging proprietary digital biomarkers and novel formulations of well-characterized CNS-active small molecules, we are accelerating clinical development to achieve rapid progress in therapeutic innovation.
Team of Experts
We are an exceptional multidisciplinary team of scientists, neuroscience drug developers, digital biomarker pioneers, and experts in commercial and regulatory affairs, all dedicated to revolutionising treatments for patients in need.
